Tempus Stock

tempus.comHealthcareFounded: 2015Funding to Date: $826.22MM

Tempus is a biotechnology company focused on making precision medicine a reality by applying AI in healthcare, deriving insights from an expansive library of clinical data and molecular data.

Register for Details

For more details on financing and valuation for Tempus, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Tempus.

Register Today

Team

Management Team

Kevin White, Ph.D.
Chief Science Officer
Vanessa Rollings
Chief Financial Officer
Eric Lefkofsky
Founder & Chief Executive Officer
Ryan Fukushima
Chief Operating Officer
Marc Yoskowitz
Chief Strategy Officer
Mike Yasiejko
Chief Commercial Officer
Gary Palmer, MD
Chief Medical Officer
Shane Colley
Chief Technology Officer
Chief Strategy Officer
Chief People Officer

Board Members

David Agus, MD
A. Keith Stewart, MB.CHB., MBA
Steve Case
Revolution
Arul M. Chinnaiyan, MD, Ph.D.
Peter Barris
New Enterprise Associates
Funmi Olopade, MD
Eric Topol, MD
John Doerr
Kleiner Perkins

Other companies like Tempus in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B

News

Pyramid will use Tempus' TIME Trial Network to identify and enroll patients eligible for a Phase I/II trial of its TRK inhibitor, PBI-200.
Groupon co-founder Eric Lefkofsky started Tempus in September 2015. This round comes comes less than 10 months after the startup raised $200 million.
Updated on: Jun 1, 2023